PMID- 22285608
OWN - NLM
STAT- MEDLINE
DCOM- 20120717
LR  - 20211021
IS  - 2152-2669 (Electronic)
IS  - 2152-2650 (Print)
IS  - 2152-2669 (Linking)
VI  - 12
IP  - 2
DP  - 2012 Apr
TI  - The importance of IGHV mutational status in del(11q) and del(17p) chronic 
      lymphocytic leukemia.
PG  - 132-7
LID - 10.1016/j.clml.2011.12.005 [doi]
AB  - Most patients with CLL with a poor-risk cytogenetic profile have an unmutated 
      IGHV sequence. Limited clinical information exists for patients with CLL who have 
      a poor-risk cytogenetic profile and a mutated or good-risk IGHV status. We 
      retrospectively screened all patients with CLL seen at our institution from 2006 
      onward who harbored a del(11q) or del(17p) CLL detected by fluorescence in situ 
      hybridization (FISH) analysis for whom an IGHV analysis was requested. In 66 
      evaluable patients, 50 (76%) had an unmutated IGHV sequence. Thirty-nine patients 
      (59%) had del(11q) and 27 patients (41%) had del(17p); no patient in this series 
      had both del(11q) and del(17p). The patients' initial clinical presentations were 
      similar in both mutational groups. Patients with an unmutated IGHV sequence were 
      more likely to receive treatment and to have a shorter survival, with an 
      estimated 3-year overall survival (OS) of 81% compared with 100% in the group 
      with a mutated IGHV sequence (log rank, P = .06). These data suggest that IGHV 
      mutational status has prognostic relevance even in patients with CLL who are 
      defined as poor risk by genomic FISH analysis.
CI  - Copyright A(c) 2012 Elsevier Inc. All rights reserved.
FAU - Gladstone, Douglas E
AU  - Gladstone DE
AD  - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 
      21287, USA. dgladst1@jhmi.edu
FAU - Blackford, Amanda
AU  - Blackford A
FAU - Cho, Eunpi
AU  - Cho E
FAU - Swinnen, Lode
AU  - Swinnen L
FAU - Kasamon, Yvette
AU  - Kasamon Y
FAU - Gocke, Christopher D
AU  - Gocke CD
FAU - Griffin, Constance A
AU  - Griffin CA
FAU - Bolanos-Meade, Javier
AU  - Bolanos-Meade J
FAU - Jones, Richard J
AU  - Jones RJ
LA  - eng
GR  - P30 CA006973/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20120128
PL  - United States
TA  - Clin Lymphoma Myeloma Leuk
JT  - Clinical lymphoma, myeloma & leukemia
JID - 101525386
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Immunoglobulin Heavy Chains)
RN  - 0 (Immunoglobulin Variable Region)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/therapeutic use
MH  - Bone Marrow Transplantation
MH  - *Chromosome Deletion
MH  - *Chromosomes, Human, Pair 11
MH  - *Chromosomes, Human, Pair 17
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunoglobulin Heavy Chains/*genetics
MH  - Immunoglobulin Variable Region/genetics
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*genetics/*mortality/therapy
MH  - Middle Aged
MH  - *Mutation
MH  - Retrospective Studies
MH  - Survival Analysis
PMC - PMC3612932
MID - NIHMS441108
EDAT- 2012/01/31 06:00
MHDA- 2012/07/18 06:00
PMCR- 2013/04/01
CRDT- 2012/01/31 06:00
PHST- 2011/10/04 00:00 [received]
PHST- 2011/12/12 00:00 [revised]
PHST- 2011/12/15 00:00 [accepted]
PHST- 2012/01/31 06:00 [entrez]
PHST- 2012/01/31 06:00 [pubmed]
PHST- 2012/07/18 06:00 [medline]
PHST- 2013/04/01 00:00 [pmc-release]
AID - S2152-2650(11)00612-4 [pii]
AID - 10.1016/j.clml.2011.12.005 [doi]
PST - ppublish
SO  - Clin Lymphoma Myeloma Leuk. 2012 Apr;12(2):132-7. doi: 
      10.1016/j.clml.2011.12.005. Epub 2012 Jan 28.